Circulating GLP-1 Levels as a Potential Indicator of Metabolic Syndrome Risk in Adult Women
Open accessThe DOI matches its Crossref record; 48 of the 51 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1), an incretin hormone, plays an important role in regulating glucose homeostasis. In this study, the applicability of circulating GLP-1 levels as an early indicator of metabolic syndrome (MetS) risk was examined. Women without diagnosed diseases were grouped according to their number of MetS risk factors (MetS RFs) (no RFs as Super-healthy, n = 61; one or two RFs as MetS risk carriers, n = 60; 3 ≤ RFs as MetS, n = 19). The circulating GLP-1 levels and homeostasis model assessment insulin resistance (HOMA-IR) scores were significantly higher in the MetS group than in the other two groups. The GLP-1 levels correlated positively with adiposity, HOMA-IR, blood pressure, and high sensitivity C-reactive protein (hs-CRP), but not with fasting glucose and lipid profiles, whose significances were maintained after adjustments for age, smoking and drinking habits, menopausal status, and total calorie intake. The GLP-1 levels also increased proportionally with the number of MetS RFs. In the MetS group, the GLP-1 levels were much higher in individuals with obesity (body mass index ≥ 25 kg/m2). In conclusion, the circulating GLP-1 level may be applicable as a potential early indicator of MetS risk in women without diagnosed diseases. Further study with a large population is needed to confirm the conclusion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although there have been several studies with GLP-1RAs demonstrating a significant reduction in hsCRP [16, 17]”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [17]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Alberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01858.x · Cited by 6,597 · cited 8×
“Since IR will lead to a gradual progression from hyperinsulinemia to glucose intolerance and eventually, T2D [10], the early detection of MetS risks (including IR) is important for the prevention of chronic metabolic diseases [9].”
BackgroundInfluentialAbdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354 · cited 8×
“Since IR will lead to a gradual progression from hyperinsulinemia to glucose intolerance and eventually, T2D [10], the early detection of MetS risks (including IR) is important for the prevention of chronic metabolic diseases [9].”
BackgroundInfluentialThe Global Epidemic of the Metabolic Syndrome
Saklayen, M. G. (2018) · Current Hypertension Reports · doi:10.1007/s11906-018-0812-z · Cited by 3,990 · cited 1×
“more of any of the following risk factors (MetS RFs): Fasting blood glucose ≥ 100 mg/dL; waist circumference (WC) ≥ 85 cm (for females); systolic BP ≥ 130 mmHg or diastolic BP ≥ 85 mmHg; TG ≥ 150 mg/dL; and HDL-C < 50 mg/dL (for females) [1,34].”
BackgroundGlobal burden of obesity in 2005 and projections to 2030
Kelly, T., Yang, W., Chen, C.-S., Reynolds, K., & He, J. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.102 · Cited by 3,319 · cited 3×
“8% by 2030 [5], the burden of metabolic abnormalities and the risks of chronic degenerative diseases such as CVD, diabetes, and cancer are likely to increase, as well.”
BackgroundInfluentialGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
The Emergence of the Metabolic Syndrome with Menopause
Carr, M. C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030242 · Cited by 1,449 · cited 1×
“This hormone also has a direct effect on glucose uptake by the skeletal muscle and adipocytes, leading to the lowering of the blood glucose concentration [46,48].”
BackgroundKieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062 · cited 2×
“When food is ingested, the proglucagon molecules in specific intestinal enterocytes (named L-cells) are cleaved to form amidated peptides that are 30 amino acids in length, named GLP-1(7-36) amide (NH2), the predominant secreted form of GLP-1 which are then secreted into the circulatory system [17].”
BackgroundDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869 · cited 4×
“In addition, fasting levels of plasma GLP-1 were significantly higher in patients with T2D than people with normal glucose tolerance (NGT), but the postprandial plasma GLP-1 area under curve was significantly lower in patients with T2D than people with NGT [11,14].”
BackgroundInfluentialGorboulev, V., Schürmann, A., Vallon, V., Kipp, H., Jaschke, A., Klessen, D., Friedrich, A., Scherneck, S., Rieg, T., Cunard, R., et al. (2012) · Diabetes · doi:10.2337/db11-1029 · Cited by 687
2018 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea
Seo, M. H., Lee, W.-Y., Kim, S. S., Kang, J.-H., Kang, J.-H., Kim, K. K., Kim, B.-Y., Kim, Y.-H., Kim, W.-J., Kim, E. M., et al. (2019) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2019.28.1.40 · Cited by 676
The gut microbiome and metabolic syndrome
Dabke, K., Hendrick, G., & Devkota, S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129194 · Cited by 654
Hansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595
Resistant starch in food: a review
Raigond, P., Ezekiel, R., & Raigond, B. (2015) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.6966 · Cited by 555
Brubaker, P. L., & Drucker, D. J. (2004) · Endocrinology · doi:10.1210/en.2004-0015 · Cited by 540 · cited 1×
“Additionally, GLP-1-mediated signaling reduces the expression of proinflammatory and proapoptotic factors, thereby improving the viability of pancreatic β-cells [18,19].”
BackgroundMenopause-Associated Lipid Metabolic Disorders and Foods Beneficial for Postmenopausal Women
Ko, S.-H., & Kim, H.-S. (2020) · Nutrients · doi:10.3390/nu12010202 · Cited by 516
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465
Yusta, B., Baggio, L. L., Estall, J. L., Koehler, J. A., Holland, D. P., Li, H., Pipeleers, D., Ling, Z., & Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.001 · Cited by 446
Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men
Gutzwiller, J.-P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031403 · Cited by 442
Muscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409
Gilbert, M. P., & Pratley, R. E. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00178 · Cited by 407 · cited 1×
“Inhibitors of DPP-4 (the enzyme that deactivates GLP-1) and GLP-1 analogs that have functions similar to those of GLP-1 have been commercialized for the treatment of diabetes [12,38] and have also recently been used for the treatment of obesity [12,38–40].”
MethodGraaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403 · cited 3×
“The active GLP-1 has a very short half-life of 1–2 min in circulation, since it is rapidly deactivated by dipeptidyl peptidase-4 (DPP-4) [20].”
BackgroundFærch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321 · cited 4×
“In addition, fasting levels of plasma GLP-1 were significantly higher in patients with T2D than people with normal glucose tolerance (NGT), but the postprandial plasma GLP-1 area under curve was significantly lower in patients with T2D than people with NGT [11,14].”
BackgroundInfluentialNäslund, E., Gutniak, M., Skogar, S., Rössner, S., & Hellström, P. M. (1998) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.3.525 · Cited by 307
Crajoinas, R. O., Oricchio, F. T., Pessoa, T. D., Pacheco, B. P. M., Lessa, L. M. A., Malnic, G., & Girardi, A. C. C. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00729.2010 · Cited by 278 · cited 2×
“GLP-1 also has diuretic and natriuretic effects that are mediated by changes in the renal hemodynamics and by the downregulation of NHE3 activity in the renal proximal tubule [45].”
BackgroundRole of resistant starch in improving gut health, adiposity, and insulin resistance
Keenan, M. J., Zhou, J., Hegsted, M., Pelkman, C., Durham, H. A., Coulon, D. B., & Martin, R. J. (2015) · Advances in Nutrition · doi:10.3945/an.114.007419 · Cited by 243
Paniagua, J. A., de la Sacristana, A. G., Sánchez, E., Romero, I., Vidal-Puig, A., Berral, F. J., Escribano, A., Moyano, M. J., Peréz-Martinez, P., López-Miranda, J., et al. (2007) · Journal of the American College of Nutrition · doi:10.1080/07315724.2007.10719633 · Cited by 227 · cited 1×
“For example, the consumption of an olive oilenriched Mediterranean diet for 28 days by individuals with abdominal obesity and IR resulted in a significantly higher blood GLP-1 concentration [33].”
Estrogen: An Emerging Regulator of Insulin Action and Mitochondrial Function
Gupte, A. A., Pownall, H. J., & Hamilton, D. J. (2015) · Journal of Diabetes Research · doi:10.1155/2015/916585 · Cited by 198 · cited 3×
“This hormone also has a direct effect on glucose uptake by the skeletal muscle and adipocytes, leading to the lowering of the blood glucose concentration [46,48].”
BackgroundObesity in menopause - our negligence or an unfortunate inevitability
Kozakowski, J., Gietka-Czernel, M., Leszczyńska, D., & Majos, A. (2017) · Menopausal Review · doi:10.5114/pm.2017.68594 · Cited by 189
iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy
Lynch, L., Hogan, A. E., Duquette, D., Lester, C., Banks, A., LeClair, K., Cohen, D. E., Ghosh, A., Lu, B., Corrigan, M., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.003 · Cited by 181 · cited 4×
“The weight loss effect of GLP-1 is induced through the activation of invariant natural killer T (iNKT) cells and the triggering of fibroblast grow factor 21 (FGF21) [35].”
BackgroundInfluentialCarr, R. D., Larsen, M. O., Jelic, K., Lindgren, O., Vikman, J., Holst, J. J., Deacon, C. F., & Ahrén, B. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2054 · Cited by 154 · cited 1×
“Most research studies have focused on the treatment of diabetes using GLP-1 agonists [15] but there have not been many strategies developed to prevent chronic degenerative diseases.”
BackgroundMetabolic Syndrome and Insulin Resistance: Perioperative Considerations
Bagry, H., Raghavendran, S., Carli, F., Warner, D. S., & Warner, M. A. A. (2008) · Anesthesiology · doi:10.1097/aln.0b013e3181649314 · Cited by 151 · cited 1×
“A reason for this phenomenon is that the central fat distribution acts as a major factor in the pathogenesis of metabolic abnormalities [42].”
BackgroundNutritional modulation of endogenous glucagon-like peptide-1 secretion: a review
Bodnaruc, A. M., Prud’homme, D., Blanchet, R., & Giroux, I. (2016) · Nutrition & Metabolism · doi:10.1186/s12986-016-0153-3 · Cited by 139 · cited 1×
“These findings suggest that an adjustment of the dietary composition can serve as a promising lifestyle strategy for managing obesity and diabetes by promoting GLP-1 secretion and its subsequent effects [31].”
BackgroundIs GLP‐1 a hormone: Whether and When?
D'Alessio, D. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12466 · Cited by 130
Tanaka, T., Yano, T., Adachi, T., Koshimizu, T., Hirasawa, A., & Tsujimoto, G. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-007-0250-y · Cited by 120
Impact of Intra-Abdominal Fat and Age on Insulin Sensitivity and β-Cell Function
Utzschneider, K. M., Carr, D. B., Hull, R. L., Kodama, K., Shofer, J. B., Retzlaff, B. M., Knopp, R. H., & Kahn, S. E. (2004) · Diabetes · doi:10.2337/diabetes.53.11.2867 · Cited by 109
Glucagon like peptide-1 (GLP-1) likes Alzheimer’s disease
Simsir, I. Y., Soyaltın, U. E., & Çetinkalp, Ş. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.03.002 · Cited by 96 · cited 5×
“Additionally, GLP-1 prevents hyperglycemia-related inflammation and apoptosis by lowering the blood sugar levels in the brain via the downregulation of PKA and phosphoinositide 3-kinase activities [36].”
BackgroundInfluentialRelationship of obesity to adipose tissue insulin resistance
Jiang, J., Cai, X., Pan, Y., Du, X., Zhu, H., Yang, X., Zheng, D., Gaisano, H., Wei, T., & He, Y. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000741 · Cited by 73 · cited 2×
“It was found that abdominal obesity accounted for approximately two-thirds of the strongest factors contributing to adipose tissue-derived insulin resistance (IR) in both men and women [9].”
BackgroundSignalling in the gut endocrine axis
Gribble, F. M., & Reimann, F. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.02.039 · Cited by 66
Recent advances in understanding the role of glucagon-like peptide 1
Reed, J., Bain, S., & Kanamarlapudi, V. (2020) · F1000Research · doi:10.12688/f1000research.20602.1 · Cited by 66
Shima, K., Suda, T., Nishimoto, K., & Yoshimoto, S. (1990) · Acta Endocrinologica · doi:10.1530/acta.0.1230464 · Cited by 64
Gut hormones and gut microbiota: implications for kidney function and hypertension
Afsar, B., Vaziri, N. D., Aslan, G., Tarim, K., & Kanbay, M. (2016) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2016.10.007 · Cited by 63 · cited 1×
“GLP-1 also has diuretic and natriuretic effects that are mediated by changes in the renal hemodynamics and by the downregulation of NHE3 activity in the renal proximal tubule [45].”
BackgroundMultiple Factors Related to the Secretion of Glucagon-Like Peptide-1
Wang, X., Liu, H., Chen, J., Li, Y., & Qu, S. (2015) · International Journal of Endocrinology · doi:10.1155/2015/651757 · Cited by 54
Glucagon, GLP-1 and Thermogenesis
González-García, I., Milbank, E., Diéguez, C., López, M., & Contreras, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143445 · Cited by 49 · cited 1×
“Moreover, the FGF21 molecules secreted by iNKT cells play an important role in activating the thermogenic process in brown adipose tissue [37].”
BackgroundAhlkvist, L., Vikman, J., Pacini, G., & Åhrén, B. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2012.06.004 · Cited by 37
Hussein, M. S., Abushady, M. M., Refaat, S., & Ibrahim, R. Y. M. (2013) · Archives of Medical Research · doi:10.1016/j.arcmed.2013.10.012 · Cited by 31
Central Functions of Glucagon-like Peptide-1: Roles in Energy Regulation and Neuroprotection
McGrath, R. T. (2015) · Journal of Steroids & Hormonal Science · doi:10.4172/2157-7536.1000.152 · Cited by 8 · cited 1×
“Additionally, the release of a small amount of GLP-1 from neurons in the nucleus tractus solitarii [22], which is regulated by food intake and meal composition [23–29], contributes to satiety by regulating energy consumption and reducing gastric motility [30–32].”
Background
Cited by
Mosenzon, O., Capehorn, M. S., De Remigis, A., Rasmussen, S., Weimers, P., & Rosenstock, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01585-7 · Cited by 91
“Although there have been several studies with GLP-1RAs demonstrating a significant reduction in hsCRP [16, 17], the impact of semaglutide on hsCRP has yet to be fully elucidated.”
BackgroundGarvey, S. M., Mah, E., Blonquist, T. M., Kaden, V. N., & Spears, J. L. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2122668 · Cited by 93
“Circulating GLP-1 concentrations were directly correlated with metabolic syndrome and obesity in a study of 140 female participants.(59) However, it is the acute response and contribution of GLP-1 to insulin regulation that is traditionally studied in oral glucose and meal challenges.”
Ahmed, M., Kumari, N., Mirgani, Z., Saeed, A., Ramadan, A., Ahmed, M. H., & Almobarak, A. O. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-021-00965-2 · Cited by 88
“found that GLP-1 plasma Levels can be a potential Indicator of MetS [47].”
BackgroundDieck, H. T., Schön, C., Wagner, T., Pankoke, H., Fluegel, M., & Speckmann, B. (2021) · Nutrients · doi:10.3390/nu14010143 · Cited by 38
“Recently, Wu et al. found out that several butyrate producers and functional potential for butyrate production were decreased both in prediabetes and in type 2 diabetes (T2D) [35], confirming earlier findings by Zhang et al. on reduced butyrate-production capacity during the progression of glucose intolerance [36].”
BackgroundInfluentialAnti-inflammatory effects of GLP-1 in patients with COVID-19
Sazgarnejad, S., Yazdanpanah, N., & Rezaei, N. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1964955 · Cited by 21
“circulating GLP-1 levels as an indicator of metabolic syndrome showed that measurement of circulating GLP-1 could be considered as an early diagnostic marker of metabolic syndrome, especially obesity [67].”
Background
Metadata
- Authors
- Seon, M. J., Hwang, S. Y., Son, Y., Song, J., & Kim, O. Y.
- Affiliations
- Dong-A University (KR)
- Chonnam National University (KR)
- Corresponding author
- Song, Juhyun
- Kim, Oh Yoen
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2021-03-06
- Volume
- 13
- Issue
- 3
- Pages
- 865
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC8001839
- OpenAlex
- W3133910378
- Cited by
- 21
- References
- 51
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 2
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation of Korea (NRF-2019R1F1A1054111, NRF-2016R1A2B4013627 and NRF-2019R1I1A3A01058861)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucagon-like peptide-1, metabolic syndrome, metabolic syndrome risk factors, insulin resistance, HOMA-IR, obesity, adiposity, C-reactive protein, blood pressure, women, incretins
- MeSH terms
- Adult, Blood Glucose, Blood Pressure, C-Reactive Protein, Fasting, Female, Homeostasis, Humans, Insulin, Insulin Resistance, Lipids, Predictive Value of Tests, Biomarkers, Risk Assessment, Metabolic Syndrome, Early Diagnosis, Adiposity, Glucagon-Like Peptide 1, Young Adult, Republic of Korea
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.